Over the past decade, the scientific community has delivered an impressive pace of scientific innovation, including breakthrough therapies and new modalities with potential to dramatically transform patient outcomes. Yet, the average time from lab to approved medicine is roughly 10 years in developed markets, such as the G7. Unfortunately, in many parts of the world, especially lower- to low-to-middle income countries, even after approval in the G7, patients may have to wait additional years for lifesaving medicines or never receive them at all. Through this multi-sectoral panel discussion, we will highlight the urgent need to create and scale innovative mechanisms to improve access to oncology medicines. This panel will endeavor to share the perspective of stakeholders from industry, government, policy, and patient advocacy organisations to identify innovative solutions that will serve patients globally.